First-Line Combination Immunotherapy Prolongs Survival in BRAF Advanced Melanoma

Elisa Becze, BA, ELS, Editor


Initial treatment with two monoclonal antibodies significantly improves survival for patients with BRAF V600-variant advanced melanoma compared to treatment with two targeted agents, researchers reported during the November 2021 ASCO Plenary Series meeting. The initial findings were so conclusive that the study’s data safety and monitoring board stopped the trial early.

View Article @

ONS Voice Articles

ONS's member magazine articles.

View All Voice Articles